In light of the ongoing shortages of obesity and diabetes medications known as GLP-1s, many patients have turned to various sources for these drugs,...
Bluebird Bio, a once-promising biotech company, made headlines recently with its decision to sell itself and its portfolio of gene therapies to investment firms...